Epidermal Growth Factor Receptors in Ovarian Cancer
Author Information
Author(s): O.J. Owens, C. Stewart, I. Brown, R.E. Leake
Primary Institution: Glasgow University
Hypothesis
What is the incidence of epidermal growth factor receptors (EGFR) in ovarian cancer and is there a correlation with tumor differentiation and disease stage?
Conclusion
EGFR was present in 39.7% of ovarian cancer samples, with no significant correlation found between its presence and tumor differentiation or disease stage.
Supporting Evidence
- EGFR was found in 39.7% of ovarian cancer samples.
- Presence of EGFR varied from 36.4% in mucinous tumors to 47.7% in undifferentiated tumors.
- Statistical analysis showed no significant difference between EGFR presence and tumor differentiation or disease stage.
Takeaway
This study looked at ovarian cancer samples to see how many had a specific receptor called EGFR, and found that about 4 out of 10 had it, but it didn't seem to matter how advanced the cancer was.
Methodology
The study analyzed 199 samples from 150 patients using a single point screen and full Scatchard analysis to determine the presence of EGFR.
Limitations
The study could not confirm the prognostic significance of EGFR due to insufficient follow-up time and the heterogeneity of ovarian tumors.
Participant Demographics
Patients included a range of ages from 25 to 88, with the majority being in stages 3 and 4 of ovarian cancer.
Want to read the original?
Access the complete publication on the publisher's website